AVCT - AVACTA GROUP - Share Chat

AVACTA GROUP Plc is a UK-based clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies and diagnostics. Its proprietary Affimer® platform provides a novel class of protein therapeutics, offering an alternative to antibodies with potential benefits in stability, size, and customisation. This technology is leveraged for both therapeutic and diagnostic applications, including rapid point-of-care tests.

The company’s therapeutic pipeline utilises its pre|CISION™ platform, designed for targeted cancer chemotherapy to enhance efficacy and reduce systemic toxicity. A key clinical asset is AVA6000, a FAP-activated doxorubicin prodrug, currently in Phase 1 trials. Avacta operates a dual strategy of internal drug development alongside out-licensing its platforms for various applications, collaborating with pharmaceutical and diagnostic partners globally.